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Abstract
Gene-based therapies for tissue regeneration involve delivering a specific gene to a target tissue
with the goal of changing the phenotype or protein expression profile of the recipient cell; the
ultimate goal being to form specific tissues required for regeneration. One of the principal
advantages of this approach is that it provides for a sustained delivery of physiologic levels of the
growth factor of interest.
This manuscript will review the principals of gene-enhanced tissue engineering and the techniques
of introducing DNA into cells. Part 2 will review recent advances in gene-based therapies for dental
hard tissue regeneration, specifically as it pertains to dentin regeneration/pulp capping and
periodontal regeneration.
i. Introduction
Current approaches to tissue regeneration include: (i) the
use of passive three-dimensional scaffolds to provide a
local environment that is conducive to new tissue forma-
tion, (ii) inductive strategies in which additional growth
factors are incorporated into a scaffold/matrix to modify
cell behavior, and (iii) strategies to form a vital construct
of cells, either fully differentiated autologous cells of the
desired type, or stem cells that have been isolated and
expanded in vitro to restore tissue function.
Gene-enhanced tissue engineering (GETE) combines
techniques of tissue engineering with gene therapy. Spe-
cifically, gene-based therapies involve delivering a specific
gene to the target tissue with the goal of changing the phe-
notype or protein expression profile of the recipient cell
[1]. This can stimulate the gene-enhanced cell and/or
neighboring uncommitted cells to differentiate into the
desired cell and tissue types. One of the principal advan-
tages of this approach is that it provides for a sustained
delivery of physiologic levels of the growth factor of inter-
est. This is in contrast to protein delivery systems, which
are often hampered by the short half life of the delivered
protein.
The central premise underpinning this approach is the
existence of a population of progenitor cells that are capa-
ble of regenerating different tissues with guidance from
local cues in the wound environment. Mammalian cells
are, of necessity, fully capable of forming the varied tissues
and organs during initial development and growth of the
organism. This regenerative ability is decreased with
aging, in part the result of a decrease in production of the
specific protein factors involved in regulating develop-
ment of these tissues [2]. The goal of gene-enhanced tissue
engineering is to reclaim this lost regenerative capacity by
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to deliver physiologic levels of these growth factors.
Based on previous studies on the regeneration of articular
cartilage [3], meniscal cartilage [4], bone [5], and dermal
wounds [6], it is apparent that the ideal graft material pro-
vides a source of cells capable of forming the desired tis-
sue when suitably induced, provides a biodegradable
scaffold for new tissue formation (a tissue conductive
environment), and provides the appropriate signals to
induce tissue formation (an inductive environment).
a. Cellular component
One of the current tenets is that embryonic, fetal, or post-
natal stem cells, isolated through complex protocols, are
required for successful tissue regeneration. However, as
discussed later, recent findings bring this view into ques-
tion.
Stem cells are undifferentiated progenitor cells that have
the capacity to self-renew, without senescence. They have
the desirable property of being capable of differentiating
into multiple, more specialized, cells that arise from any
of the three germ layers. Stem cells can be identified based
on their expression of early mesenchymal stem cell mark-
ers, such as STRO-1 and CD146/MUC18. In contrast,
"progenitor" or "precursor" cells are similar to stem cells,
but lack the ability to self-renew [7].
The challenge to using stem cells for tissue regeneration is
to direct their differentiation along the desired pathway.
Besides their ability to differentiate into multiple cell
types, stem cells also interact with stromal tissue in the site
of implantation, thereby repopulating the desired cell
types. This property, known as homing, is believed to be
regulated by signaling molecules in the local environment
[8]. Additional approaches used to drive differentiation of
stem cells towards the desired cell type include co-cultur-
ing with an isolate from the desired tissue type, the use of
inductive cell culture conditions (e.g. supplementation of
media with growth factors), and genetic modification
[9,10].
(i) Fetal stem cells
Since the initial isolation and characterization of human
embryonic stem cells from fetal blastocytes [11], there has
been significant interest in the potential use of these cells
for tissue regeneration. Although fetal cells appear to have
great potential in the field of tissue engineering, ethical,
religious and political concerns, as well as a paucity of cell
lines, have dampened this enthusiasm. This has been
compounded by concerns over the possibility of tissue
rejection and recent evidence pointing to the potential for
teratoma and teratocarcinoma formation [12]. In order to
circumvent some of these issues, other potential sources
of stem cells are actively being explored; including placen-
tal-derived stem cells [13] and umbilical cord blood [14].
(ii) Postnatal adult stem cells
Postnatal adult stem cells are multipotential cells that,
under the appropriate stimulus, can be induced to
develop into a number of different cell types within a spe-
cific tissue, including osteoblasts, odontoblasts, adi-
pocytes, and neuronal-like cells [15]. Potential sources of
postnatal stem cells include bone marrow-derived mesen-
chymal stem cells [16], muscle-derived stem cells [17] and
adipose tissue-derived stem cells [18]. In vitro, multipo-
tent adult stem cells appear to be capable of undergoing
trans-differentiation to form other tissue types, although
the significance of this phenomenon in vivo is unclear [7].
Overall, adult stem cells appear to be more limited in
potential compared to embryonic stem cells, are difficult
to harvest in sufficient quantity, and require specialized
isolation techniques. As with fetal stem cells, recent evi-
dence that raises the specter of tumorigenicity
[19,20]means that additional research will be required
prior to the widespread use of adult stem cells for tissue
regeneration.
(iii) Genetically-enhanced adult cells
Recent findings bring into question the dogma that either
fetal or adult stem cells are necessary for successful tissue
regeneration. Certain mammalian cell types can be
induced to dedifferentiate to progenitor cells when stimu-
lated with appropriate signals [21]. A population of
fibroblast-like cells isolated from fat, dermis, and gingiva
have significant hard tissue regenerative potential, but
only when supplemented with specific growth factors;
either by genetic enhancement or through supplementa-
tion with recombinant proteins [22-27].
Our results [23,5] suggest that relatively crude prepara-
tions of fibroblast-like cells can potentially serve as a
source of "differentially plastic" cells for tissue regenera-
tion when enhanced with signaling molecules and with
guidance from local cues in the wound environment. No
extensive purification techniques or ex vivo expansion of
cells are required. These are not true "stem cells" because
they are only capable of regenerating tissue when geneti-
cally-enhanced with specific growth factors or morpho-
gens.
b. Scaffold/carrier
A biodegradable matrix is required for ease of delivery of
cells to the wound site as well as to provide a three-dimen-
sional scaffold to preserve the space of the defect in antic-
ipation of the formation of new tissue. The ideal scaffold
for tissue engineering should be relatively easy to handle,
allow for the incorporation of cells, allow for the free dif-Page 2 of 10
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ment of a vascular bed to ensure survival of the implanted
cells, induce a minimal inflammatory response and be
ultimately biodegraded. In contrast to orthopedic situa-
tions, in which the scaffold must be strong enough to
immediately tolerate considerable biomechanical forces,
strength may be less of a concern when regenerating rela-
tively small periodontal or dental defects. This however
does not obviate the need to consider the effect of biome-
chanical effect of occlusal forces on both the dentition
and surrounding tissues. From the perspective of a pulp
capping agent, as well as for periodontal regeneration, it
would be advantageous to have a malleable or injectable
formulation, allowing it to adapt to the shape of the
defect. From a regulatory standpoint, there are obvious
benefits to using materials that are already approved for
clinical use.
A large number of matrix materials have been employed
in tissue engineering [28,29], ranging from long-lasting
porous hydroxyapatite ceramics to naturally-occurring
molecules of intermediate duration (e.g. alginate, colla-
gen, chitosan), to relatively short-lasting polymers such as
polyglycolic acid (PGA) and polylactic acid (PLA) and
their copolymer poly(lactic-co-glycolide) (PLGA).
Although this latter group of man-made polymers has
been widely used, they have some inherent disadvantages.
Their breakdown products can have an adverse effect on
wound healing [28]. Moreover, added cells require "seed-
ing" onto the matrix material, which requires ex vivo cell
culturing for extended periods of time. In addition, cells
often have difficulty in adhering to the polymer.
Type I collagen, a major component of bone, dental pulp
and periodontal ligament, is biocompatible and has been
shown to promote regeneration of hard tissue defects in
various models [28]. However, collagen-based systems, by
themselves, are structurally weak. The porous nature of
alginate gels, a biodegradable polysaccharide, allows for
the migration of cells and regulatory proteins inside the
network [30]. Chemical modification designed to couple
the rate of alginate degradation to new tissue formation
can significantly increase the rate of tissue regeneration
[31].
Constituents of the extracellular matrix play a crucial role
in mineralization, cell adhesion and differentiation [32].
Methods to improve the properties of scaffold materials
by introducing biomimetic motifs (e.g. the introduction
of integrin-binding peptide sequences) have tremendous
potential in the field of tissue regeneration [33].
Ultimately, no one matrix material will be suitable for all
situations. Mixtures of two or more materials, designed to
take advantage of the ideal mechanical and/or biologic
properties of the individual components, will likely turn
out to hold the most promise.
c. Morphogens/growth factors
The regulation of both tooth formation and periodontal
attachment formation is mediated by a complex cascade
of interactions [34] involving four principal protein fami-
lies: the bone morphogenetic proteins (BMPs), fibroblast
growth factors (FGFs), and the mutually inhibitory hedge-
hog and Wnt family of proteins.
Of these, the BMPs appear to be key regulators involved in
the formation of new bone and dental hard tissues. BMPs
are a family of growth factors that exert their function, in
part by stimulating the differentiation of non-committed
precursor cells into osteoblasts [35]. A number of recent
articles have reviewed the potential for BMP delivery in
human bone regeneration [36-38].
ii. Gene delivery systems
A. Benefits and disadvantages of available systems for 
introducing DNA into cells
The use of GETE for tissue regeneration requires that genes
are introduced into cells by some methodology. Many
methods of gene transfer exist, each with their own inher-
ent strengths and weaknesses. This section will review the
benefits as well as the disadvantages of the methods cur-
rently in use as well as some of the newer techniques
being developed.
The diverse techniques for introducing nucleic acids into
cells are most frequently grouped under the general cate-
gories: chemical, physical, and viral. When chemical or
physical means are used, these are examples of transfec-
tion. When replication incompetent viral vectors are used,
the term is transduction. The introduction of DNA by




Calcium phosphate co-precipitation of DNA was first
described over 30 years ago [39] and continues to be used
today mainly due to its low cost and reasonable transfec-
tion efficiency. DNA is combined with calcium chloride
and further mixed with phosphate-buffered saline and
incubated at room temperature. A DNA/calcium phos-
phate precipitate forms which, when added drop wise to
cells in culture, is endocytosed. The majority of the inter-
nalized DNA is destroyed by cytoplasmic nucleases but a
small amount avoids that fate, and is transported to the
nucleus where the genes are expressed transiently for 2–3
days [40]. In a small number of cells (often in the range of
one per hundred thousand), the DNA can integrate into
the genome randomly and if a selectable marker is presentPage 3 of 10
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clones or populations.
Advantages of this method are the low cost and simple
procedure. Disadvantages include sensitivity to impurities
in DNA preparations and to minor changes in pH, salt
concentration, and temperature; often resulting in poor
reproducibility. This method is largely being replaced by
lipid-based approaches which, although more costly, gen-
erally give consistently better transfection efficiencies.
(ii) DEAE-dextran
Diethylaminoethyl (DEAE)-dextran was one of the first
chemical reagents used for DNA transfer into cells [41].
DEAE-dextran is a cationic polymer that associates with
negatively-charged nucleic acids. Excess polymer in the
DEAE-dextran/DNA complex enables the complex to
associate with the negatively-charged cell membrane
where it is endocytosed. Transient, but not stable, expres-
sion of transferred DNA follows. Advantages of this
method are low cost, simplicity, and reproducibility. Dis-
advantages include lack of utility for obtaining stable
transfection and the fact that it is effective only for a lim-
ited number of cell types such as macrophages. DEAE-dex-
tran has largely been replaced by newer, more versatile
technologies.
(iii) Lipids
Artificial liposomes were first used to deliver DNA to cells
as early as 1980, however, the popularity of this method
increased dramatically with the advent of cationic lipids
for transfection or "lipofection" as this method is now
called [42]. Many types of lipids are used to lipofect cells,
hence the many lipofection products on the market. In
general, cationic lipids contain a positively-charged head
group, such as an amine, attached to a linker group with
at least two hydrophobic tail groups. The cationic portion
of the lipid molecule associates with the negatively-
charged nucleic acids to form a complex. The overall net
positive charge of the complex allows for closer associa-
tion with negatively-charged cellular membranes. Follow-
ing endocytosis, the complexes appear in endosomes and
are destined for destruction in lysosomes. To prevent this
destruction of the DNA, the lipid mixture also contains a
neutral lipid (i.e. L-dioleoylphosphatidylethanolamine;
DOPE) that facilitates release of the DNA from the endo-
somes, thereby freeing up the DNA to make its way to the
nucleus.
Advantages of this method are the ability to transfect a
large number of cell types, high efficiency transient trans-
fection, ease of use, and good reproducibility. Disadvan-
tages include the high cost relative to calcium phosphate
and DEAE-dextran, the observation that some primary
cells (neurons, dendritic cells, endothelial cells) are not
effectively lipofected, and the fact that lipofection is not
effective for direct in vivo application where serum is
present. Overall, lipofection still remains the most popu-
lar method for in vitro transfection.
(iv) Polymers
Organic polymers have also been used for transfection.
One polycation, polyethylenimine (PEI), is an organic
macromolecule with a high cationic charge density. When
PEI is complexed with DNA, the DNA is condensed into
positively-charged particles that interact with the nega-
tively-charged proteoglycans on the cell surface and enter
cells via endocytosis. Once inside the endosomes, the PEI
causes endosomal swelling and rupture, thus releasing the
DNA into the cytoplasm and ultimately into the nucleus
[43].
Advantages include ease of use and high transfection effi-
ciency in some cell types as well as applicability for in vivo
use [44]. Disadvantages include cost and the fact that not
as many cell types are transfectable with this approach as
compared to lipofection.
(v) Proteins
Proteins and peptides are sometimes used to enhance
DNA transfer by cationic lipids. Proteins such as integrins
[45] and transferrin [46] and peptides such as protamine
sulfate [47] and nuclear localization signal peptides [48]
have been used to improve transfection efficiency in cer-
tain cell types. The disadvantage of using proteins and
peptides is that they increase the cost and complexity of
the system.
b. Physical methods
Physical and mechanical methods of gene transfer have
the advantage of simplicity and avoidance of the use of
chemicals or viral proteins, which can potentially elicit an
immune response. Disadvantage of these approaches is
that they are mainly limited to transient expression in
most tissue except muscle, where longer-term expression
can be obtained.
(i) Biolistic
Using the biolistic method, DNA is coated onto metal
microparticles and "shot" into cells at high velocity by
electrostatic force or gas pressure [49]. Hence, this method
is sometimes referred to as a "gene gun".
Advantages of this system are the simplicity of the
method, no limitations to cell type transfected, and no
limit on size and number of genes transfected. The major
disadvantage is low efficiency of transfection. Relatively
few cells take up and express the DNA. In addition, there
is potential damage to tissues when used in vivo. ThisPage 4 of 10
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applications.
(ii) Electroporation
Electroporation involves treatment of cells with a very
rapid pulse of high voltage current that results in a pertur-
bation of the cell membrane and transient pore forma-
tion. The DNA passes through the pores and into the
cytoplasm. Advantages of this system are that it can theo-
retically work on any cell type and there are no size limi-
tations to the DNA. Disadvantages include: significant
effort is required to optimize the technique (duration and
strength of pulse) for each cell type, a relatively high
degree of cell death is observed, and transfection effi-
ciency is often low in comparison to other methods. This
method is most applicable to in vitro studies. However,
there have been reports of in vivo use [50].
A variation on electroporation known as nuclear electro-
poration (or nucleofection) involves direct electropora-
tion of nucleic acids into the nucleus [51]. Advantages of
this approach include the ability to bypass blocks in trans-
location of nucleic acid from the cytoplasm to the
nucleus. The system is a good alternative to viral
approaches for difficult to transfect primary cell lines. Dis-
advantages include the high cost of the equipment and
reagent buffers and the fact that optimal conditions must
be identified for each cell type used. Overall, it is a good
option for in vitro transfection when other non-viral meth-
ods fail.
(iii) Microinjection
Direct injection of DNA into the nucleus of a cell using
glass micropipettes has mainly been used in embryonic
stem cells and other cultured cell lines [52]. Advantages of
this system include high transfection efficiency and the
lack of size limitations on the DNA injected. Disadvan-
tages are many. This technique requires an investment in
specialized equipment and personnel training and auto-
mation of the process is costly. Microinjection is currently
not practical for the majority of gene transfer applications
that require the production of large numbers of trans-
fected cells.
(iv) Naked DNA
Some tissues, particularly muscle, can be transfected with
DNA alone without any other transfection reagents. This
accidental discovery was reported in 1990 [53], when it
was observed that DNA without transfection reagent actu-
ally transfected mouse muscle better than liposome/DNA
complexes. This technique can be used to very effectively
transfect muscle cells in vitro. However, it does not work
well for other cell types nor does it work as well in vivo;
possibly due to degradation of the DNA prior to cellular
uptake.
c. Viral vectors
Viruses have evolved over millennia to efficiently intro-
duce genes into living cells. With the technological break-
throughs in molecular biology since the 1970s, it has
become possible for molecular virologists to engineer dif-
ferent types of infectious viruses into gene delivery sys-
tems called viral vectors. To create viral vectors, key genes
in a wild type viral genome are deleted, creating a defec-
tive viral genome that is incapable of producing infectious
viruses in cells (replication incompetent). Removal of the
key viral genes not only renders the viral genome replica-
tion defective, but also creates the space needed for inclu-
sion of a therapeutic or marker gene. Hence, a "viral
vector" genome is created that contains viral regulatory
elements, packaging signals, other viral coding sequences,
as well as therapeutic genes. However, the viral vector can-
not reproduce itself.
Viral vector genomes must be propagated in special cell
lines called packaging cells or vector producer cell lines. In
these special cell lines, the key viral genes that were
removed from the viral genome are expressed separately
(in trans) from the viral vector genome such that all of the
viral proteins needed for assembly of viral particles are
expressed. Thus, the viral vector producer cell line pro-
duces "viral vector particles" that contain the viral vector
genome. The viral vector particles are used to deliver the
therapeutic genes to target cells in a process called trans-
duction. Once inside target cells, the vector genome
expresses the therapeutic genes and any other viral genes
included in the vector genome. Because some key viral
genes are missing from the vector genome, the target cells
cannot produce wild type viruses or more viral vector par-
ticles. Thus, viral vectors are replication incompetent.
Because so many viruses are being studied by a multitude
of virologists, it can be expected that more viral-based
gene delivery systems will be developed in the coming
years. Although there are many viral vector delivery sys-
tems, none are ideal for all gene transfer applications.
Each viral system has unique strengths and weaknesses.
(i) Adeno-associated virus (AAV)
AAV is a parvovirus and its genome consists of a single-
stranded DNA approximately 4.7 kb in length. There are
several serotypes of AAV, with AAV2 being most com-
monly used in gene transfer experiments.
Advantages of AAV are that they can transduce many dif-
ferent cell types both in vitro and in vivo, they transduce
non-dividing cells as well as dividing cells, they remain
episomal and, in some cell types, can express transgenes
for months without integration. They have been used
safely in several gene therapy clinical trials. Wild type AAV
can integrate preferentially into human chromosome 19.Page 5 of 10
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the genome frequently nor do they preferentially target
chromosome 19. The vast majority of people are seropos-
itive for AAV, which is a non-pathogenic virus often asso-
ciated with adenoviral infections. Different serotypes of
AAV have differing cell type preferences and elicit different
immune responses [54]. Disadvantages of AAV include its
small packaging capacity and difficulty in producing
helper-free stocks of AAV at high titer. AAV will continue
to grow in popularity due to the fact that it does not inte-
grate into the genome; a key problem with other viral sys-
tems. However large scale production remains
problematic.
(ii) Adenovirus (Ad)
Adenoviruses (Ad) are group I double-stranded DNA
viruses with linear genomes approximately 36 kbp in
length. They are commonly used in gene therapy experi-
ments.
Ad vectors have a number of advantages including the fact
that they can be easily produced at high titer, they trans-
duce a wide range of cells, they can transduce both divid-
ing and non-dividing cells (although like other viruses,
they are more effective at transducing dividing cells), they
remain episomal in the nucleus and do not integrate, and
they can transiently express transgenes at a high level
extending from approximately 2–10 days post-transduc-
tion, after which time expression can continue at very low
levels. Hence, Ad vectors are mainly useful for transient
expression (7–8 days). Disadvantages of Ad vectors
include the transient nature of expression if longer expres-
sion is required, and immunogenicity can be severe. It is
often not possible to give repeat administrations of Ad
vectors because of neutralizing antibodies elicited from
earlier Ad administration. Packaging capacity is also not
as large as with other systems. However, in light of the
increased regulatory scrutiny given to integrating vector
systems, use of Ad vector technology will likely increase.
In addition, newer Ad vector systems designed to reduce
immunogenicity, such as the gutless system, are continu-
ally being developed [55].
(iii) Herpes simplex virus (HSV)
HSV is another group I double-stranded DNA virus with a
linear genome of 150 kbp in length. Advantages of HSV
include its large packaging capacity (~ 30 kbp), ability to
transduce a wide variety of cell types (especially those in
the nervous system), and the fact that both dividing and
non-dividing cells can be transduced. It can be produced
at high titer and does not integrate into the genome [56].
Disadvantages include the potential for significant toxic-
ity due to expression of viral proteins.
(iv) Lentivirus (lenti)
Lentivirus vectors (lentivector) belong to the group VI
class of RNA viruses that reverse transcribe their RNA.
These belong to the same class of retrovirus as HIV-1, the
causative agent of AIDS. The most popular lentivirus vec-
tor systems are based on HIV-1 [57]. However, lentivector
systems based on viruses that do not normally infect
humans have also been developed.
The major advantage that lentivectors have over oncoret-
roviral systems is the ability to transduce non-dividing cell
types as well as dividing cells. Lentivectors can also express
genes long term due to the fact that they integrate into the
genome. They are not very immunogenic. Because they
integrate into the genome, insertional mutagenesis is now
a significant concern of regulatory agencies. However, this
should not be problematic for basic science research. Pro-
duction systems for lenti are not as efficient as compared
to other viral systems. Production of modest amounts of
lentivector is labor intensive. The packaging capacity of ~8
kbp often necessitates that cDNAs be used. Transgene
expression levels are relatively low.
(v) Oncoretrovirus (retro)
Oncoretroviruses are also group VI class RNA viruses. Ret-
roviral vectors based on Moloney murine leukemia virus
[58] are the most commonly used viral vectors in human
gene therapy trials. Advantages and disadvantages of the
retro system are similar to those of the lentiviral system
except that retros cannot transduce non-dividing cells.
Lentiviral vectors have nuclear localization signals on
some of their viral proteins which act to facilitate trans-
port of the preintegration complex through the nuclear
membrane. Oncoretroviral proteins lack these signals.
Therefore the oncoretroviral preintegration complex can-
not access the nucleus until nuclear membrane break-
down occurs during cell division. This can be problematic
for in vivo use because most cells are not actively dividing
in the body. However, this is generally not problematic
when working with cells in culture (in vitro applications).
A major advantage of retros over lentivectors is that they
are much easier to produce at high titer because stable
producer lines are relatively simple to generate and they
produce retroviral vector particles without need of
repeated transfections. It is anticipated that regulatory
approval of retros-based clinical techniques will become
more problematic now that documented cases of inser-
tional mutagenesis causing cancer have appeared [59].
(vi) Other viral vector systems
Polio [60], sindbis [61], and SV40 [62] are among a large
group of viruses being developed for gene transfer appli-
cations. Each will have specific niche applications as viral
gene delivery systems.Page 6 of 10
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A. Overview of current approaches
The principal drawback with any cell-based regenerative
tissue therapy is the individualized nature of this type of
approach. As currently performed, these techniques
require harvesting of a portion of the patients tissue (e.g.
hematopoietic bone marrow), isolation of stem cells, ex
vivo expansion, followed by transplantation back into the
patient. This is both time consuming and labor intensive.
The development of universal donor stem cell lines could
potentially obviate this requirement. Prior to widespread
use of such an approach, the potential for tissue rejection
would have to be addressed. While this might necessitate
pharmacologically-mediated immune suppression, recent
evidence suggests that allogeneic adult stem cells have a
number of mechanisms that allow them to circumvent
host immune responses [63-65]. Moreover, cell encapsu-
lation appears to decrease the risk of an immune response
[66], possibly via antigenic masking.
Alternatively, a simplified approach could be developed
that eliminates the need for extensive purification of har-
vested tissue. This can be accomplished by using mini-
mally-processed harvested tissue that has been
genetically-enhanced with specific growth factors (i.e.
gene-enhanced tissue engineering).
B Factors to be considered when developing new 
regenerative techniques
A number of issues should be considered prior to develop-
ing any tissue engineering approach for pulpal and/or per-
iodontal regeneration.
(a) Regulatory issues
Early contact with government regulatory agencies such as
the Food and Drug Administration in the United States
(FDA) is essential to eliminate or reduce areas of potential
regulatory concern. As previously discussed, principal
components in any tissue regeneration product will
include one or more of: 1) a cellular component, 2) a pro-
tein or gene transfer agent, and 3) a synthetic matrix to
contain the first two components. The key to success is
selecting individual components that will have the best
likelihood of obtaining regulatory approval.
(i) Cells
Although each situation is different, regulatory issues for
cellular components become increasingly more complex
when moving from autologous to allogeneic cells. In
addition to the source of cells, the cell type and the need
for characterization of cells is a key issue to regulatory
agencies. It is important to point out that it is not essential
that cellular components be "purified". This is often
incorrectly stated as an FDA requirement by companies
that have patented cell-type specific purification proce-
dures. The FDA is primarily concerned with "characteriza-
tion" of the cells; one of the principal goals being to
address concerns that the product is safe and consistent in
formulation. Purification per se is not required and, in
fact, attempts to develop a system requiring the isolation
of specific cell types may prove detrimental to the ultimate
goal of marketing a clinically viable product.
(ii) Growth factor delivery systems
A growth factor/protein is often included as one compo-
nent of a tissue regenerative product. This can be delivered
in a number of ways: as exogenously produced protein, as
a gene product delivered directly via plasmid DNA or viral
vector, or as part of a cellular therapy where the cells are
genetically-enhanced to overexpress specific genes. Direct
protein delivery is the easiest approach from a regulatory
standpoint. Gene-enhanced cell delivery systems involve
significantly more regulatory hurdles. The choice of gene
delivery system also has important regulatory considera-
tions. Transient expression systems are preferred over sys-
tems involving prolonged expression. Integrative vector
systems, in which the transgene and/or viral vector inte-
grates into the target cell genome, are used in situations
where therapeutic gene expression is desired for pro-
longed periods. However, it has now been documented
that integration of genes/viral vectors can result in tumor
formation [59]. As a result, regulatory agencies may
require that all patients receiving integrative vector sys-
tems be monitored for life as part of the clinical trial. This
makes the use of integrating vector systems impractical for
wide-spread use. For this reason, the use of a non-integrat-
ing vector system is preferred for transgene delivery.
(iii) Matrix
The matrix is used to contain the cells and/or other com-
ponents of the tissue regenerative product. Tissue regener-
ative agents that contain a cellular component in addition
to other matrix materials are classified as "combination
products" by the FDA, meaning that the product is part
device and part biologic. From a regulatory standpoint, it
is preferable to use materials that have been previously
approved for clinical use. Otherwise, the required safety
studies of each individual component will make the Phase
I trial safety design considerably more difficult. Where
possible, matrix materials should be from non-mamma-
lian sources (e.g. alginate).
(iv) Animal models
Multiple animal models may have to be developed.
Before considerable effort is made in the development of
animal models for pre-clinical studies, the appropriate
regulatory agencies should be contacted to ascertain if the
animal models chosen will be acceptable. Regulatory
agencies sometimes require use of specific large animalPage 7 of 10
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on project cost and logistics as many research facilities
cannot house large animals. It is important that these
issues be discussed with regulatory agencies prior to com-
mencement of animal studies.
(b) Practical considerations
Any new technology intended for widespread clinical
usage should be based, in large part, on currently existing
methodologies. This will reduce the time and effort
required to bring the product to market. Consideration of
how the technology can be applied en masse should also
be anticipated.
(i) Cellular component
Allogeneic cells must be expanded in culture, character-
ized and tested for genetic stability and infectious agents
prior to use. Their principal advantage lies in the fact that
one cell line could potentially be marketed as a single tis-
sue regenerative product to treat many different patients.
Immune rejection and genetic drift/instability of cultured
cells are two issues that need to be addressed. It is also
apparent that human embryonic stem cell lines can
acquire genetic changes in culture and have the potential
of transforming into teratomas. Consequently, for tissue
regenerative procedures, the use of autologous cells is pre-
ferred over allogeneic donor cells, thereby eliminating the
potential for immunological rejection and disease trans-
mission.
In order to develop a cost-effective autologous tissue
regenerative product, it is crucial to avoid techniques
requiring ex vivo cell expansion. This necessitates using a
tissue that contains an abundant amount of easily harvest-
able donor cells that can be obtained with minimal donor
site morbidity.
(ii) In vivo versus ex vivo approaches
Ex vivo culture techniques are labor intensive, time con-
suming, and require that cells be extensively characterized
to rule out the acquisition of genetic mutations. Direct in
vivo application of gene transfer vectors (e.g. direct injec-
tion of the gene transfer vector into the patient) likewise
remains a challenge. Practical considerations include tar-
geting the vector to the desired target cells, avoidance of
significant first pass loss in the liver or lungs, resistance to
destruction by human serum complement, and demon-
strated non-targeting of germ cells.
Development of novel combination approach involving
in vitro binding of vector to host cells for a short period of
time followed by reintroduction of the vector-bound cells
in an implantable matrix holds significant potential. The
actual cellular transduction would occur in vivo, but
because the cells are held in vitro for only a short period of
time to allow for vector binding, no ex vivo cell expansion
is required.
(iii) Gene transfer systems
The choice of gene transfer system must be tailored to the
specific needs of each application. For genetic enhance-
ment of an autologous cell product, the efficiency of gene
transfer is a paramount consideration. Since non-viral
gene transfer systems tend to be inefficient, it is preferable
to use a viral vector delivery system; ideally one with an
established record of clinical use. Due to the regulatory
issues described earlier, it is not prudent at this time to use
integrating viral vectors. Since transgene expression on the
order of one week may be long enough to allow for the
transdifferentiation of cells, adenovirus vector system are
a good option for many applications. The major drawback
with adenoviral systems is the potential for significant
immunogenicity to the adenoviral vector proteins. This
problem can be greatly reduced through the use of matrix
materials that mask these epitopes.
(iv) Ease of translation into a clinical protocol
Ideally, the entire process of donor tissue harvest, process-
ing of the tissue, transduction, matrix assembly, and re-
implantation of vector-bound cells should take place as a
single outpatient procedure in the clinical setting, without
the need for specialized equipment or extensive training.
C. Funding sources
Obtaining funding to transition from the research phase
to commercial production of cell-based therapies can be
challenging. Venture capitalists have been reluctant to
invest in these firms because of historically low rates of
return on investment as well as concerns over patent
rights [67]. While the United States Patent and Trademark
Office has issued a number of patents on human-derived
cells, foreign countries have been reluctant to issue similar
patent protection. These factors should be considered
early on, since the ultimate objective is the development
of a tissue regenerative product that will succeed both in
the clinical setting and in the marketplace.
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